ROQUEFORT THERAPEUTICS PLC

Report Publication Announcement • Mar 22, 2021

National Storage Mechanism | Additional information

RNS Number : 9396S

Roquefort Investments PLC

22 March 2021

22 March 2021

roquefort investments PLC

("Roquefort Investments" or the "Company")‎

Admission to Trading & First Day of Dealings

Roquefort Investments plc, an investment company established to acquire businesses focused on early stage opportunities in the medical biotechnology sector, is pleased to ‎announce that following the publication of its prospectus on 17 March 2021, the admission of the Company's entire issued share capital to the Official List of the UKLA by way of a ‎standard listing under Chapter 14 of the UKLA's Listing Rules and to trading on the London Stock ‎Exchange's main market for listed securities.

The Company also completed a placing ‎of 20,000,000 shares at 5p per share raising a gross amount of £1 million.

Dealings will commence at 8.00 a.m. today under the TIDM "ROQ". ‎The Company's ISIN is GB00BMDQ2T15 and SEDOL number is BMDQ2T1.‎

The Prospectus is available to be viewed at the Company's website at: www.roquefortinvest.com

Stephen West, Chairman of Roquefort Investments, commented: "The team behind Roquefort Investments is delighted to be commencing this journey as a listed business.  We have a clear growth strategy focused on an exciting market where we believe there are highly compelling opportunities that will deliver value for our shareholders, as well as value for the businesses that we ultimately acquire. The funds raised will enable Roquefort Investments to progress the formal screening of opportunities and we look forward to providing details in due course when we find an appropriate target to move on."

Enquiries:

Roquefort Investments plc
Stephen West (Chairman)	+44 (0)20 3290 9339
Optiva Securities Limited (Broker)
Christian Dennis	+44 (0)20 3411 1881

About Roquefort Investments

Roquefort Investments was formed as an investment company to acquire businesses focused on early-stage opportunities in the medical biotechnology sector with the aim of generating optimal returns for both the target businesses and our shareholders.  It is envisaged that such acquisition or acquisitions will trigger a reverse takeover in accordance with the listing rules.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

LISSEIFISEFSEDD